Severe Psoriasis Pipeline Analysis Report 2026

Report Coverage

The Severe Psoriasis Pipeline Analysis Report by Expert Market Research gives comprehensive insights into severe psoriasis therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for severe psoriasis. The severe psoriasis report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The severe psoriasis pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with severe psoriasis treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to severe psoriasis.

Read more about this report - Request a Free Sample

Severe Psoriasis Pipeline Outlook

The severe psoriasis pipeline outlook reflects a shift beyond conventional management approaches, which typically include systemic biologics targeting IL-17, IL-23, and TNF pathways, alongside emerging oral small-molecule inhibitors. Despite these options, unmet needs remain for durable efficacy, safety, and novel mechanisms. Pipeline activity is increasingly focused on innovative disease-modifying strategies.

Severe psoriasis treatment continues to evolve as regulatory progress underscores ongoing innovation in this space. In January 2026, FibroBiologics filed a Phase 1/2 IND with the U.S. FDA for CYPS317, an investigational allogeneic fibroblast spheroid therapy for moderate-to-severe psoriasis. Supported by encouraging preclinical data, the candidate represents a novel, cell-based approach aimed at modulating inflammatory pathways and advancing treatment options beyond established biologic and oral therapies.

Severe Psoriasis Epidemiology

Severe psoriasis epidemiology reflects a significant global disease burden, with overall psoriasis affecting an estimated 43 million people worldwide based on physician/dermatologist-diagnosed cases, and up to 102 million when self-reported cases are included. Prevalence varies widely by region and genetic background, from under 1 % in some areas to several percentage points in high-income regions, with adults more commonly affected than children. Strengthening global surveillance initiatives is expected to generate more comprehensive and reliable prevalence insights in the coming years.

Severe Psoriasis – Pipeline Therapeutic Assessment

Severe Psoriasis Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase III covers a major share of the total severe psoriasis clinical trials. Phase III accounts for the largest share at 52.1%, followed by phase II at 28.8%, phase IV at 11.0%, phase I at 8.2%, while early-phase programs represent 0.0%.

Severe Psoriasis Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under the severe psoriasis pipeline analysis include monoclonal antibodies, small-molecule inhibitors, and fusion proteins. The severe psoriasis report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for severe psoriasis. In December 2025, Takeda announced positive Phase 3 results for its oral TYK2 inhibitor zasocitinib in moderate-to-severe plaque psoriasis. The once-daily therapy met all primary and secondary endpoints, with more than half of patients achieving near-clear or clear skin, reinforcing its potential as a leading oral treatment option.

Severe Psoriasis Clinical Trials – Key Players

The EMR report for the severe psoriasis pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed severe psoriasis therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in severe psoriasis clinical trials:

• Guangdong Hengrui Pharmaceutical Co., Ltd
• SFA Therapeutics
• Usynova Pharmaceuticals Ltd.
• UCB Biopharma SRL
• Shanghai Huaota Biopharmaceutical Co., Ltd.
• LEO Pharma
• Spyre Therapeutics, Inc.
• Huabo Biopharm Co., Ltd.
• Haisco Pharmaceutical Group Co., Ltd.

Severe Psoriasis – Emerging Drugs Profile

Key Questions Answered in the Severe Psoriasis Pipeline Insight Report

• Which companies/institutions are leading the severe psoriasis drug development?
• Which company is leading the severe psoriasis pipeline development activities?
• What is the current severe psoriasis commercial assessment?
• What are the opportunities and challenges present in the severe psoriasis pipeline landscape?
• What is the efficacy and safety profile of severe psoriasis pipeline drugs?
• Which company is conducting major trials for severe psoriasis drugs?
• Which companies/institutions are involved in severe psoriasis collaborations aimed at providing enhanced therapeutic alternatives for patients?
• What are the geographies covered for clinical trials in severe psoriasis?

Reasons To Buy This Report

The Severe Psoriasis Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for severe psoriasis. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into severe psoriasis collaborations, regulatory environments, and potential growth opportunities.

Related Reports

Global Clinical Trials Market

Psoriasis Treatment Market

Psoriasis Epidemiology Forecast

Severe Psoriasis Epidemiology Forecast